Atypical Teratoid Rhabdoid Tumor Across Two Decades: Real-World Outcomes from a Latin-American Institution
Neuro-Oncology Pediatrics · 05.11.2026
DOI: 10.1093/neuped/wuag059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Pediatrics, online erschienen am 05.11.2026. Verfasst von Jéssica Benigno Rodrigues und 14 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
AND KEYWORDS Background Atypical teratoid/rhabdoid tumor (ATRT) is a rare, highly aggressive central nervous system tumor of early childhood, with scarce data from Latin America. We describe the clinical features, treatment, and outcomes of pediatric ATRT at a Latin-American tertiary center.
Methods
Retrospective study of patients <18 years with ATRT treated at the Institute of Pediatric Oncology (IOP/GRAACC/UNIFESP) from 2000 to 2022. Patients <3 years old received high-dose chemotherapy with autologous stem cell transplantation, with or without focal radiotherapy; patients ≥3 years old received conventional chemotherapy and craniospinal radiotherapy.
Results
Thirty-one patients were included (median age, 1.0 year; range, 0.3–14.4). Among the 24 patients <3 years old, 3-year PFS and OS were 13.8% and 24.6%, respectively. Absence of metastases was associated with higher 3-year PFS (23.7% vs. 0%, p = 0.011) and OS (35.6% vs. 10%, p = 0.021), and metastatic disease remained an independent adverse prognostic factor (HR 3.70; 95% CI 1.11–12.29; p = 0.033). First-line radiotherapy was associated with improved 3-year OS (66.6% vs. 7.8%, p = 0.004); however, in a landmark analysis of the 12 patients who completed first-line treatment, this association was attenuated and non-significant (53.3% vs. 22.2%, p = 0.14). Of the seven patients ≥3 years old (median follow-up, 1.8 years), three were alive at last follow-up. Genetic alterations included SMARCB1, NOTCH1, and KMT2D.
Conclusions
ATRT outcomes remain poor in this cohort, and metastatic disease independently predicted worse survival. First-line radiotherapy was associated with improved survival in children <3 years, but this was attenuated in the landmark analysis; prospective studies are needed to define its role and timing.
Zitieren
APA
Rodrigues, J. B., Silva, N. S. D., Cappellano, A. M., Cavalheiro, S., Dastoli, P. A., Costa, M. D. S. D., Almeida, D. B., Dassi, N., Alves, M. T. S., Silva, F. A. B., Chen, M. J., Figueiredo, M. L. S., Toledo, S. R. C. D., Gamba, F. T., & Caran, E. M. M. (2026). Atypical Teratoid Rhabdoid Tumor Across Two Decades: Real-World Outcomes from a Latin-American Institution. Neuro-Oncology Pediatrics. https://doi.org/10.1093/neuped/wuag059
Vancouver
Rodrigues JB, Silva NSD, Cappellano AM, Cavalheiro S, Dastoli PA, Costa MDSD, et al. Atypical Teratoid Rhabdoid Tumor Across Two Decades: Real-World Outcomes from a Latin-American Institution. Neuro-Oncology Pediatrics. 2026. doi:10.1093/neuped/wuag059
BibTeX
@article{Rodrigues2026,
author = {Rodrigues, Jéssica Benigno and Silva, Nasjla Saba da and Cappellano, Andrea Maria and Cavalheiro, Sergio and Dastoli, Patricia Alessandra and Costa, Marcos Devanir Silva da and Almeida, Daniela Barbosa and Dassi, Natalia and Alves, Maria Teresa Seixas and Silva, Frederico Adolfo Benevides and Chen, Michael Jenwei and Figueiredo, Maria Luisa Sucharski and Toledo, Silvia Regina Caminada de and Gamba, Francine Tesser and Caran, Eliana Maria Monteiro},
title = {Atypical Teratoid Rhabdoid Tumor Across Two Decades: Real-World Outcomes from a Latin-American Institution},
journal = {Neuro-Oncology Pediatrics},
year = {2026},
doi = {10.1093/neuped/wuag059}
}
EUVIMED